Site is Being Upgraded

Awakening the sleeping/cancer-protecting angels in mutant p53-expressing human tumors: Emodin, isolated from Rhubarb and others,  increases the expression of tumor suppressors genes, such as SOCS1/6, TET1, TA-p73, TAp63, p53, and others, induces regression of p53-mutated human tumors, via down-regulation of its target gene, 8/August/2018, 10.23 pm

Combinatorial therapy for gynecologic cancers: A therapeutic mix encompassing  Gedunine, Dianhydrogalactitol, EGCG, Salinomycin, Simvastatin and Fluoxetine (GDESSF) inhibits the expression of HDAC6, acetylates tumor suppressor proteins, activates tumor suppressor function, and stifles the progression of ARID1A-mutated ovarian cancers via up-regulation of its target gene, 8/August/2018, 10.14 pm
August 8, 2018
Androgens come to the rescue of anxiety and depression: Testosterone, a male reproductive steroid hormone, decreases PHF8 levels, increases the expression of serotonin receptors Htr1a and Htr2a, and promotes resistance to stress-induced -anxiety and -depression, via down-regulation of its target gene, 10/August/2018, 9.45 am
August 10, 2018
Show all

From Significance of the study to Public health relevance

Given that: (1) cancer suppressor p53 is mutated in more than 50% of human cancers of different tissue origin; (2) p53 pathway is altered in about 80% of tumors.; (3) our understanding is incomplete in terms of molecular targets and the oncogenic/malignant pathways involved in mutant p53-overexpressing tumors; (4) cancer causes the highest economic loss compared to all the known causes of death worldwide; and (5) cancer causes the considerable economic loss worldwide, there is an urgent need to find: (i) a cheaper alternative to the existing expensive drugs; (ii) a side-effect-free natural product-based drug; and (iii) a way to effectively treat and stall metastatic progression and relapse of mutant p53-overexpressing human cancers.


From therapeutic strategy to Research Findings:

(i) Therapeutic strategy: 

This study suggests a therapeutic strategy for stalling the progression of p53-deficient/deleted or mutant-p53 expressing metastatic cancers. By activating tumor suppressor p53’s unmutated “homologous protein such as TAp73/p63” in p53-deficient or mutant-p53 expressing metastatic cancer cells, one can stall their progression.

(ii) Research findings:  

Emodin has been shown to function as an anticancer agent in a number of cancers. However, the mechanism of action remains largely unknown.

Figure 1. Mechanistic insight into how  Emodin functions as an anticancer/antimetastatic agent in mutant p53-expressing tumors.  Emodin,  by activating tumor/metastasis suppressor genes, such as SOCS1/6, TET1, p53, TAp63, TAp73 and others, in metastatic tumors, it may inhibit the progression of mutant-p53 expressing human cancers.

Figure 2. Emodin functions as an anti-tumor/metastatic agent through induction of tumor/metastatic suppressor genes, such as SOCS1/6, TET1, p53, TAp63 and TAp73.

This study suggests that Emodin may function as an anti-cancer/metastasis agent by increasing the expression a number of tumor/metastasis suppressor genes

Emodin, by increasing the expression of its target gene, it may increase the expression of tumor/metastasis suppressors genes, such as   SOCS1/6, TET1, TA-p73, TAp63, p53, and others. Thereby, it may inhibit the migration and invasion of metastatic cancer cells expressing mutant-p53 (figure1).

 


Therapeutic opportunity:

Given the ability of Emodin to induce the expression of a number of tumor/metastasis suppressor genes, it may be used, either alone or in combination with other anticancer drugs, to inhibit the progression of p53-mutated invasive metastatic tumors. Taken together, this study suggests, for the first time, that oncologists may consider treating terminally ill metastatic cancer patients with Emodin, as it may stall the progression of advanced metastatic cancers. Given its low cost compared to other anti-cancer/metastatic agents, it may be a preferred anti-cancer/metastatic agent (figure 2).


Details of the research findings

Idea Proposed/Formulated by Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $300#

Undisclosed mechanistic information: How Emodin increases the expression of tumor suppressor genes, such as SOCS1/6, TET1, TA-p73, TAp63, p53, and others,  in mutant p53 expressing cancer cells?

For purchase and payment details, you may reach us at admin@genomediscovery.org

#Research cooperation

[easy_payment currency=”USD”]


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L., Awakening the sleeping/cancer-protecting angels in mutant p53-expressing human tumors: Emodin, isolated from Rhubarb and others,  increases the expression of tumor suppressors genes, such as SOCS1/6, TET1, TA-p73, TAp63, p53, and others, induces regression of p53-mutated human tumors, via down-regulation of its target gene, 8/August/2018, 10.23 pm, Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at admin@genomediscovery.org

Comments are closed.